www.fdanews.com/articles/149801-boehringer-completes-phase-iii-studies-of-nintedanib

Boehringer Completes Phase III Studies of Nintedanib

September 28, 2012

Boehringer Ingelheim Pharmaceuticals has completed clinical trial enrollment of two Phase III studies evaluating the safety and efficacy of nintedanib (BIBF 1120).
Pharmaceutical Business Review